Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France

Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France

Objective: To update the health economic evaluation of pirfenidone in the treatment of idiopathic pulmonary fibrosis (IPF) compared to all available alternatives strategies (Best supportive care – BSC and nintedanib), based on a cost-utility model previously validated by the CEESP’s (French Committe...

Full description

Bibliographic Details
Main Authors: Emilie Clay, Olivier Cristeau, Romain Chafaie, Alexandrina Pinta, Benjamin Mazaleyrat, Vincent Cottin
Format: Article
Language:English
Published: Taylor & Francis Group 2019-01-01
Series:Journal of Market Access & Health Policy
Subjects:
pirfenidone
nintedanib
idiopathic pulmonary fibrosis
health-economic model
cost-effectiveness
france
ceesp
esbriet
ofev
cost-utility
Online Access:http://dx.doi.org/10.1080/20016689.2019.1626171

Internet

http://dx.doi.org/10.1080/20016689.2019.1626171

Similar Items